Suppression of matrix metalloproteinase production from synovial fibroblasts by meloxicam in-vitro

Journal of Pharmacy and Pharmacology

Volumn 58, Issue 3, 2006, Pages 359-366

  Asano, Kazuhito ^a   Sakai, Misako ^a   Matsuda, Takako ^a   Tanaka, Hironori ^a   Fujii, Keigo ^a   Hisamitsu, Tadashi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; MELOXICAM; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG SYNOVIAL FLUID LEVEL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIUM;

AGED; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; MATRIX METALLOPROTEINASES; NF-KAPPA B; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; THIAZINES; THIAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644767994     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.58.3.0010     Document Type: Article

References (45)

1. Altman, R. D. (1997) The syndrome of osteoarthritis. J. Rheumatol. 24: 766-767
2. Asano, K., Kamakazu, K., Hisamitsu, T., Suzaki, H. (2003) Suppressive activity of macrolide antibiotics on nitric oxide production from nasal polyp fibroblasts in vitro. Acta Otolaryngol. 123: 1064-1069
3. Dean, D. D., Martel-Pelletier, J., Pelletier, J. P., Howell, D. S., Woessner, J. F. (1989) Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 84: 678-685
4. Domeij, H., Yucel-Lindberg, T., Modeer, T. (2002) Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. Eur. J. Oral Sci. 110: 302-306
5. Engelhardt, G., Bogel, R., Schnitzler, C., Utzmann, R. (1996) Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem. Pharmacol. 51: 29-38
6. Fenner, H. (1998) Differential target tissue presentation and cyclooxygenase-2 and -1 inhibition by non-steroidal anti-inflammatory drugs. In: Vane, J. R., Botting, R. M. (eds) Clinical significance and potential of selective COX-2 inhibitors. William Harvey Press, London, pp 31-39
7. Gendron, C., Kashiwagi, M., Hughes, C., Caterson, B., Nagase, H. (2003) TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett. 555: 431-436
8. Grodzinsky, A. J., Levenston, M. E., Jin, M., Frank, E. H. (2000) Cartilage tissue remodeling in response to mechanical forces. Annu Rev. Biomed. Eng. 2: 691-713
9. Hayakawa, T., Yamashita, K., Ohuchi, E., Shinagawa, A. (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107: 2373-2379
10. Herouy, Y., Mellios, P., Bandemir, E., Dichmann, S., Nockowski, P., Schopf, E., Norgauer, J. (2001) Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J. Dermatol. Sci. 25: 198-205
11. Jasin, H. E. (1989) Immune mechanisms in osteoarthritis. Semin. Arthritis Rheum. 18: 86-90
12. Jin, G., Sah, R. L., Li, Y. S., Lotz, M., Shyy, J. Y., Chien, S. (2000) Biomechanical regulation of matrix metalloproteinase-9 in cultured chondrocytes. J. Orthop. Res. 18: 899-908
13. Joussen, A. M., Poulaki, V., Mitsiades, N., Kirchhof, B., Koizumi, K., Dohmen, S., Adamis, A. P. (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 16: 438-440
14. Kafienah, W., Al-Fayez, F., Hollander, A. P., Barker, M. D. (2003) Inhibition of cartilage degradation - a combined tissue engineering and gene therapy approach. Arthritis Rheum. 48: 709-718
15. Kanai, K., Asano, K., Hisamitsu, T., Suzaki, H. (2004) Suppression of MMP production from nasal fibroblasts by macrolide antibiotics in vitro. Eur. Respir. J. 23: 671-678
16. Kim, S. J., Jeong, H. J., Choi, I. Y., Lee, K. M., Park, R. K., Hong, S. H., Kim, H. M. (2005) Cyclooxygenase-2 inhibitor SC-236 [4-[5-(4-chlorophenyl)- 3-(trifluoromethyl)-1-pyrazol-1-1]benzensulfonamide] suppresses nuclear factor-kappa B activation and phosphorylation of p38 mitogen activated protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase in human mast cell line cells. J. Pharmacol. Exp. Ther. 314: 27-34
17. Knauper, V., Lopez-Otin, C., Smith, B., Knight, G., Murphy, G. (1996) Biochemical characterization of human collagenase-3. J. Biol. Chem. 271: 1544-1550
18. Kobayashi, M., Squires, G. R., Mousa, A., Tanzer, M., Zukor, D. J., Antoniou, J., Feige, U., Poole, A. R. (2005) Role of interleukin-1 and tumor necrosis factor α in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum. 52: 128-135
19. Kundu, J. K., Chun, K. S., Kim, S. O., Surh, Y. J. (2004) Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse MAPKs and AP-1 as potential molecular targets. Biofactors 21: 33-39
20. Liacini, A., Sylvester, J., Li, W. Q., Zafarullah, M. (2002) Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 21: 251-262
21. Martel-Pelletier, J., Pelletier, J. P., Fahmi, H. (2003) Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum. 33: 155-167
22. Masuhara, K., Nakai, T., Yamaguchi, K., Yamasaki, S., Sasaguri, Y. (2002) Significant increase in serum and plasma concentrations of matrix metalloproteinases-3 and -9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum. 46: 2625-2631
23. Nagase, H. (1995) Human stromelysins-1 and -2. Methods Enzymol. 248: 449-470
24. Nagase, H., Woessner, J. F. (1999) Matrix metalloproteinases. J. Biol. Chem. 274: 21491-21494
25. Nakamura, H., Yoshino, S., Kato, T., Tsuruha, J., Nishioka, K. (1999) T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage 7: 401-402
26. Nishida, K., Miyazawa, S., Inoue, H. (2003) Pathology of osteoarthritis. J. Joint Surg. 22: 26-32
27. Ogino, K., Hatanaka, K., Kawamura, M., Katori, M., Harada, Y. (1997) Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 55: 44-53
28. Pairet, M., van Ryn, J. (1998) Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm. Res. 47 (Suppl. 2): S93-S101
29. Pelletier, J. P., Mineau, F., Faure, M. P., Martel-Pelletier, J. (1990) Imbalance between the mechanisms of activation and inhibition of metalloproteinases in the early lesions of experimental osteoarthritis. Arthritis Rheum. 33: 1466-1476
30. Pillinger, M. H., Rosenthal, P. B., Tolani, S. N., Apsel, B., Dinsell, V., Greenberg, J., Chan, E. S. L., Gomez, P. F., Abramson, S. B. (2003) Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 171: 6080-6089
31. Reunanen, N., Westermarck, J., Hakkinen, L., Holmstrom, T. H., Elo, I., Eriksson, J. E., Kahari, V. M. (1998) Enhancement of fibroblast collagenases (matrix metalloproteinase-1) gene expression by ceramide is mediated by exracellular signal-regulated and stress-activated protein kinase pathway. J. Biol. Chem. 273: 5137-5145
32. Roy-Beaudry, M., Martel-Pelletier, J., Pelletier, J. P., M'Barek, K. N., Christgau, S., Shipkolye, F., Moldovan, F. (2003) Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloproteinase-1 and matrix metalloproteinase-13 induction. Arthritis Rheum. 48: 2855-2864
33. Sadowski, T., Steinmeyer, J. (2001) Effects of non-steroidal anti-inflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 9: 407-415
34. Sakai, T., Kambe, F., Mitsuyama, H., Ishiguro, N., Kurokouchi, K., Takigawa, M., Iwata, H., Seo, H. (2001) Tumor necrosis factor a induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-κB: abrogation of the tumor necrosis factor α effect by proteosome inhibitors. J. Bone Miner. Res. 16: 1272-1280
35. Shinmei, M., Masuda, K., Kikuchi, T., Shimomura, Y., Okada, Y. (1991) Production of cytokines by chondrocytes and its role in proteoglycan degradation. J. Rheumatol. Suppl. 27: 89-91
36. Shishodia, S., Koul, D., Aggarwal, B. B. (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J. Immunol. 173: 2011-2022
37. Simon, C., Goepfert, H., Boyd, D. (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92000 type IV collagenase secretion and in vitro invasion. Cancer Res. 58: 1135-1139
38. Specter, T. D., Hart, D. J., Nandra, D., Doyle, D. V., Mackillop, N., Gallimore, J. R., Pepys, M. B. (1991) Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 40: 723-727
39. Uchida, M., Shima, M., Shimoaka, T., Fujieda, A., Obara, K., Suzuki, H., Nagai, Y., Ikeda, T., Yamato, H., Kawaguchi, H. (2000) Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. J. Cell Physiol. 185: 207-214
40. Westacott, C. I., Sharif, M. (1996) Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin. Arthritis Rheum. 25: 254-272
41. Wingfield, P. T., Sax, J. K., Stahl, S. J., Kaufman, J. K., Palmer, I., Chung, V., Corcoran, M. L., Kleiner, D. E., Stetler-Stevenson, W. G. (1999) Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TEMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J. Biol. Chem. 274: 21362-21368
42. Woessner, J. (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5: 2145-2154
43. Yamada, H., Kikuchi, T., Nemoto, O., Obata, K., Sato, H., Seiki, M., Shinmei, M. (1996) Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by human articular chondrocytes. J. Rheumatol. 23: 1739-1743
44. Yang, T. E., Hawkes, S. P. (1992) Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 89: 10676-10680
45. Yuan, G. H., Masuko-Hongo, K., Sakata, M., Tsuruha, J., Onuma, H., Nakamura, H., Aoki, H., Kato, T., Nishioka, K. (2001) The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum. 44: 1056-1070